Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Oral arsenic for the treatment of APL in China

Hong-Hu Zhu • 25 Feb 2019
ISAL 2019
Acute Promyelocytic Leukemia Leukemia Rare Diseases All-trans retinoic acid Arsenic trioxide

Hong-Hu Zhu, MD, PhD, of The First Affiliated Hospital, Zhejiang University, Hangzhou, China, discusses the use of oral arsenic for the treatment of acute promyelocytic leukemia (APL) in China. Previous intravenous formulations of arsenic trioxide and all-trans retinoic acid (ATRA) meant that patients were required to visit the hospital for treatment. Now patients can complete post-remission treatment at home, greatly improving their quality of life. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Hong-Hu Zhu

VAG regimen drives immune reprogramming and superior remission in older/unfit patients with AML
3:15
VAG regimen drives immune reprogramming and superior remission in older/unfit patients with AML
Hong-Hu Zhu • 6 Dec 2025
MRD detection for AML in China & MFC to detect CEPBA mutations
1:27
MRD detection for AML in China & MFC to detect CEPBA mutations
Hong-Hu Zhu • 25 Feb 2019

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals